us pipelin visibl increas capital-expenditure control boost
stay posit increas tp
balanc sheet strengthen good expect cipla turn
net cash pipelin visibl increas low competit
respiratori file one second gadvair
third like larg product like gabraxan grevlimid
good execut brand gener market india
south africa reduct capital-expenditure control
near-term momentum good albuterol key contributor
profit expect mn sale share
shortag normalis still great product
besid gadvair file cipla file one mdi inhal
work anoth expect file
view file mdi like either gflovent hfa
gqvar market size mn market size
larg low competit opportun
call takeaway product
level cost impact due covid neutral-to-posit
ep chang factor albuterol usd/inr
albuterol key contributor profit market
expect albuterol high report mn
sale quarter albuterol shortag us
cipla receiv acceler approv mention
confer call alreadi built-up stock therefor could
suppli much receiv approv market share
iqvia current like go unlik
cipla take time ramp-up approv posit
surpris cipla alreadi hint toward stagger ramp-up
expect meaning share ramp-up mainli cipla
take share time lupin approv pace ramp-up
lupin still remain key cipla current build mn sale
albuterol account profit want
stress fact three brand interchang
market prior genericis prescript written
gener albuterol proport would like gone
segment cipla get share brand besid
cipla turn net cash cipla gener
strong reduc debt bn spent bn
dividend paid interest bn rest use
acquisit privat equiti stake consum divis cipla improv
work capit cipla like pay mn
tramadol iv even post could turn net cash
help good cash flow albuterol esomeprazol
strong respiratori file momentum us cipla
complet phase trial gadvair file soon cipla
also mention file one respiratori product
view either gflovent hfa gqvar around
mn drug cipla also mention phase trial
current on-going anoth partner mdi asset increas traction
respiratori product increas visibl us pipelin cipla also
strong product gabraxan grevlimid
estimate pot chg tp
number share mn
chg prev ep
increas target price stay posit cipla good
gener help cipla net cash increas
pipelin visibl respiratori file larg product like
gabraxan grevlimid stabl cash flow brand
gener market india south africa chang
ep factor higher-than-expect sale
albuterol launch esomeprazol suspens ep declin
due weak result target price base
ep npv gabraxan grevlimid
strong india weak us india rx busi growth
good yoy key therapi respiratori urolog cardiolog
 continu perform well gx busi also perform well
yoy growth howev cautiou india pharma growth
due fewer patient visit potenti mute anti-infect season
cipla sale us sale low mn vs
cse mn us sale show signific benefit
forward buy also impact due apotex entri dymista
margin impact goa facil remedi cost higher
relat cost cipla also mention sale bn
defer impact quarter margin bp
mention resum manufactur oper
vs level global cost front cipla said
larg neutral given higher cost incur manufactur
site maintain social distanc hygien norm larg
off-set lower promot expens brand gener market
term work capit temporari rise inventori
manufactur level stockist continu carri suffici inventori
elong receiv hospit
asset out-licens goa warn letter cipla
respond us fda end gadvair file
us approv may take month like
opportun best
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori cipla limit cipl bo
signifi initi assumpt coverag
price rate histori inc iqv
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori lupin ltd lupn bo
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
charl martineau pm univers toronto purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
